Wednesday, 15 July, 2020

Gilead Sciences to test inhaled version of Covid-19 treatment, Remdesivir

Covifor would be available in injectable vials of 100 Covifor would be available in injectable vials of 100
Gustavo Carr | 01 July, 2020, 10:58

The company's anti-viral drug was the first treatment that was found to be effective against Covid-19, the illness caused by the novel coronavirus.

Cipla has said that its version of remdesivir would be priced below Rs 5,000. India's top doctors discuss if this is the beginning of the end of the coronavirus crisis.

The other lot will be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week's time, in order to meet the emergency requirements, said the spokesperson.

The drug now is being manufactured at the company's formulation facility in Hyderabad.

"This situation is very atypical, which is why one must assume, that it will be the European Union, which goes in and negotiates with Gilead about a given quantity", Denmark's public drug procurement office said.

PTI reported that the drug will be available only through hospitals and government outlets.

The drug has received emergency use approval for severely ill patients in South Korea and the United States, and full approval in Japan.

Divided Supreme Court sides with school-choice advocates
Several attempts to provide tax credits for scholarship programs have failed amidst constitutional questions. Alliance for Open Society International Inc.-in May via teleconference due to COVID-19 shutdowns.

On June 13, ANI had reported that the top drug regulator granted permission to Hetero and another pharmaceutical firm for marketing authorization of anti-viral drug Remdesivir only for "restricted emergency use" on hospitalized COVID-19 patients with moderate disease (those on oxygen).

Apart from Hetero, Cipla has signed licensing agreements with US-based Gilead Sciences Inc, the unique producer of Remdesivir, to make and promote the drug.

The company said it has fixed a maximum retail price of Rs 5,400 per vial for the drug.

The assessment ended with recommendations that are mainly based on survey data NIAID-ACTT-11 sponsored by the National Institute of Allergy and infectious diseases of the United States, as well as on data of other studies on ramdevpir.

The total includes 14,894 deaths and 1,86,514 active cases along with 2,71,696 patients who have been cured or discharged and one patient who migrated out of India.

Maharashtra, Delhi and Tamil Nadu are among the worst-affected states in India due to the pandemic.